
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Includes Information on Inactivated, Injectable Influenza Vaccine and LAIV for Patients Aged 6 Months and Older
Includes Information on Inactivated, Injectable Influenza Vaccine and LAIV for Patients Aged 6 Months and Older
•






